SCHEMBL4313670

SCHEMBL4313670

CC(=O)SCC(=O)CCCCCCC(=O)c1cc2ccccc2s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 3/20 0.49
HDAC4 P56524 3/20 0.49
HDAC1 Q13547 3/20 0.49
HDAC7 Q8WUI4 3/20 0.49
HDAC2 Q92769 3/20 0.49
HDAC10 Q969S8 3/20 0.49
HDAC11 Q96DB2 3/20 0.49
HDAC8 Q9BY41 3/20 0.49
HDAC6 Q9UBN7 3/20 0.49
HDAC9 Q9UKV0 3/20 0.49
HDAC5 Q9UQL6 3/20 0.49
BCL2L1 Q07817 1/20 0.44
RAB9A P51151 1/20 0.43
SLC9A1 P19634 2/20 0.39
ICMT O60725 1/20 0.39
HRH4 Q9H3N8 1/20 0.39
CNR1 P21554 1/20 0.39
CNR2 P34972 1/20 0.39
DYRK1A Q13627 1/20 0.39
ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3378057 1.00 HDAC3 (0.49) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL3380570 0.82 BCL2L1 (0.51) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL4308244 0.82 BCL2L1 (0.51) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL9048628 0.80 RAB9A (0.60) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL7384635 0.78 BCL2L1 (0.53) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL4526358 0.76 BCL2L1 (0.54) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL8537206 0.76 BCL2L1 (0.57) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL3383078 0.76 HDAC1 (0.68) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL13783956 0.76 HDAC1 (0.68) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL3379610 0.74 HDAC8 (0.63) HDAC3HDAC4HDAC1HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181971-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. 2009-07-16 US disclosed
US-20090181971-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. 2009-07-16 US disclosed
US-20090181971-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. 2009-07-16 US disclosed
US-7288567-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2007-10-30 US disclosed
US-7288567-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2007-10-30 US disclosed
EP-1524262-A1 Inhibitors of histone deacetylase Methylgene, Inc. (CA) 2005-04-20 EP disclosed
EP-1280764-A2 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2003-02-05 EP disclosed
US-20020115826-A1 Inhibitors of histone deacetylase 92229129 QUEBEC INC. (CA) 2002-08-22 US disclosed
WO-2001070675-A2 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE, INC. (CA) 2001-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115826-A1 Inhibitors of histone deacetylase HDAC1, HDAC5, HDAC3 HDAC3 3/4885HDAC4 8/4885HDAC1 1/4885
US-20090181971-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC5, HDAC3 HDAC3 3/4885HDAC4 8/4885HDAC1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.